Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor monotherapy after coronary stenting in acute myocardial infarction
2021-000823-11Phase 2Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ticagrelor in myocardial infarction (MI), coronary arteriosclerosis and acute coronary syndrome (ACS), sponsored by Sahlgrenska University Hospital. Primary endpoint: Primary composite outcome at 3 months. Started May 2021; status: active.
02
Drugs
ticagrelor
03
Conditions
myocardial infarction (MI)coronary arteriosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2021-000823-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000823-11.